Skip to main content
Elderly man wearing glasses gives a piggyback ride to a girl with long curly hair in an outdoor setting with green fields and trees in the background.

Dosing and Administration

There are no clinically meaningful differences between MERILOG (insulin aspart-szjj) injection 100 Units/mL and Novolog.

Comparable dosing approach to NovoLog® with individualized titration

  • The dosing of MERILOG™ is 1:1 with NovoLog1-3
  • Dosage should be determined by an HCP and individualized and adjusted based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal1
  • Dosage adjustments may be needed with changes in physical activity, meal patterns  (ie, macronutrient content or the timing of food intake), changes in renal or hepatic function, or during acute illness1

Dosing Recommendations by Patient Status

Icon of a person and a plus sign in an orange circle.

Starting New Patients

  • Start MERILOG in the same   manner that patients would be started on NovoLog1,3
  • Patients should be monitored closely during the dose adjustment period1
Icon of a standing person with bidirectional arrows in an orange circle.

Transferring Patients

  • MERILOG has 1:1 unit dosing with NovoLog and is available in the  SoloStar pen1,2,4
  • When switching from another insulin to MERILOG, a different dosage of MERILOG may be needed1
Icon of a gear in an orange circle.

Optimize Glycemic Control

  • Consider adjusting the total daily dose, injection frequency, or timing of injection based on individual patient needs and treatment goals.¹
Illustration showing MERILOG (insulin aspart-szjj) injection 100 Units/mL SoloStar Pen with labeled components including the pen cap, cartridge holder, rubber seal, insulin scale, plunger*, insulin name, dose window, dose pointer, dose selector, and injection button, with a note stating MERILOG is also available in a 10-mL vial and a footnote indicating that the plunger will not be visible until a few doses have been injected.

HCP, health care professional; T1D, type 1 diabetes; T2D, type 2 diabetes.

Important Safety Information

Contraindications 
MERILOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin aspart products or any of the excipients in MERILOG.

Warnings and Precautions
Never share a MERILOG SoloStar® prefilled pen between patients, even if the needle is changed: Sharing poses a risk for transmission of blood-borne pathogens. 

Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. Changes in insulin regimen may affect glycemic control and predispose to hyperglycemia or hypoglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. 

Hypoglycemia is the most common adverse reaction associated with insulins, including MERILOG and may be life-threatening. 

Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between MERILOG and other insulins, instruct patients to always check the insulin label before each injection. 

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including MERILOG. If hypersensitivity reactions occur, discontinue MERILOG, treat per standard of care and monitor until symptoms and signs resolve. 

All insulin products, including MERILOG, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia. 

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, and particularly when used with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs. 

Adverse Reactions
Adverse reactions observed with insulin aspart products include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine). 

Important Safety Information for MERILOG SoloStar
MERILOG SoloStar is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise, they may not get the correct amount of insulin, which may affect their blood glucose levels.

Click here for full Prescribing information for MERILOG.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Indication

MERILOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Important Safety Information

Indication

References 

1. MERILOG Prescribing Information. Sanofi.

2. Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020;22(2):85-95.

3. ClinicalTrials.gov. NCT03202875. Available at: https://clinicaltrials.gov/study/NCT03202875. Accessed June 17, 2025

4. Kapitza C, Nosek L, Schmider W, Teichert L, Nowotny I. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes. Diabetes Technol Ther. 2020;22(4):278-284.

NovoLog is a registered trademark of Novo Nordisk A/S MAT-US-2502961-v1.0-07/2025

Back to top
sanofi_campus_logo
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.